Ludger News

March/April 2025

Ludger Vtag Glycopeptide Analysis Kit

Prepare your MAb samples for analysis in 2 hours

Ludger V-Tag system is designed for the **analysis of glycopeptides** generated from the digestion of therapeutic glycoproteins such as monoclonal antibodies (mAb). It is comprised of two steps which can be completed in **2 hours** (see workflow below).



LudgerClean A Cartridges for Glycopeptide Enrichment

LudgerClean A cartridges are designed to **remove excess dye as well as residual non-glycosylated peptides that interfere with the analysis**. They are part of the LT-VTAG-24 kit, but are also sold separately and can used to enrich unlabelled glycopeptide samples before their analysis using **MALDI/LC-MS** as shown below.



Due to their efficacy and robustness, these kits are the **preferred choice of world-leading pharmaceutical organisations**. At Ludger, they are used in our internal research projects and daily quality control.

Visit our website to learn more about **glycopeptide preparation**, **labelling** and analysis. Our team of experts have prepared a list of materials that will guide you through the process.

Please **contact us** if you require additional information.

Intercept Kick-Off Meeting in Berlin

On February 19th, Ludger's team participated in the **INTERCEPT Kick-Off Meeting** in Berlin. This gathering brought together leading experts from Europe, the United States, and South Korea to outline the project's roadmap, tackle key challenges, and set the initiative into motion.

Funded by the Innovative Health Initiative with a €38 million budget, **INTERCEPT** is a groundbreaking effort in Crohn's Disease research. By harnessing advanced biomarker technology, the project seeks to identify individuals at high risk of developing the disease—enabling early intervention before symptoms emerge. This transformative approach could significantly reduce the physical, emotional, and financial burdens for millions of patients and families worldwide.

At Ludger Ltd, **our cutting-edge glycan analysis technology plays a pivotal role in validating biomarkers** that may revolutionise early detection and prevention. Our commitment to scientific excellence and innovation aligns seamlessly with INTERCEPT's mission: transforming Crohn's Disease from a chronic, incurable condition into a manageable challenge.

Alongside our global partners, we are paving the way for a healthier future. Join us in supporting this life-changing initiative.

Ludger involved in advancing mucin glycan analysis!

Ludger is proud to be at the forefront of glycobiology research, providing essential tools and expertise that empower groundbreaking studies. A recent publication in **Nature Microbiology**, titled **"Carbohydrate-active enzymes from *Akkermansia muciniphila* break down mucin O-glycans to completion"**, led by **Dr Lucy Crouch** and collaborators, highlights the biochemical characterisation of key carbohydrate-active enzymes (CAZymes) involved in mucin degradation—an essential process in gut microbiome dynamics and human health.



Our comprehensive range of glycan analysis products and services ensures researchers have reliable resources to advance their understanding of complex carbohydrate interactions. This study utilised advanced glycan analysis workflows, including:

- **Fluorescent labelling of released O-glycans** using the LudgerTag™ Procainamide Glycan Labelling Kit (**LT-KPROC-96**) and its associated workflow.

- **LC–FLD–ESI–MS Analysis** – Procainamide-labelled samples were analysed using liquid chromatography-electrospray ionisation mass spectrometry, providing detailed molecular insights into glycan composition.

As the field of glycobiology continues to evolve, Ludger remains committed to delivering high-quality products and services to meet the emerging needs of researchers worldwide. Together with our collaborators, we strive to unravel the complexities of glycosylation and its impact on health and disease.

Join our Glycotechnology News Service

Subscribe